Dissecting the cellular and molecular immune interactions in human atherosclerosis
剖析人类动脉粥样硬化中的细胞和分子免疫相互作用
基本信息
- 批准号:9227033
- 负责人:
- 金额:$ 8.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-15 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:Anti-Inflammatory AgentsAnti-inflammatoryArterial Fatty StreakAtherosclerosisBloodCCL2 geneCREB1 geneCXCL1 geneCXCL10 geneCardiovascular DiseasesCardiovascular systemCarotid Artery DiseasesCellsCharacteristicsChronicClinicalClinical DataClinical ResearchComplexComputer AnalysisCytometryDataDiseaseEGF geneEnrollmentEventGene Expression ProfileGenesGoalsHumanImmuneImmune SeraImmune responseImmune systemInflammationInterferonsKnowledgeLigandsLipidsMAPK14 geneMeasuresMolecularMolecular ProfilingMolecular TargetMorbidity - disease rateOperative Surgical ProceduresPatientsPeripheral Blood Mononuclear CellPhenotypePlasmaPlatelet-Derived Growth FactorProcessed GenesProductionPublic HealthRNARNA ProcessingRNA analysisRandomized Clinical TrialsRegimenResidual stateRoleSamplingSignal PathwaySiteStagingStrokeSystems BiologyTechniquesTechnologyTestingTissuesTransient Ischemic AttackVariantVirus Diseasesclinical phenotypecytokinedimensional analysisdisabilityimmune activationimprovedinnovative technologiesmortalitynext generationnext generation sequencingnovelplatelet-derived growth factor BBresponsestandard of care
项目摘要
PROJECT SUMMARY
Cardiovascular disease (CVD) due to atherosclerosis is the leading cause of mortality and
disability globally. Even in patients treated with optimized standard-of-care regimens, residual
morbidity and mortality remain high. New strategies that directly target atherosclerosis—the
main cause of CVD—are urgently needed. Although recent conceptual advances have
emphasized the importance of chronic inflammation and immune system activation in
atherosclerosis in CVD, new promising anti-inflammatory agents tested in randomized clinical
trials showed no benefits in either reducing cardiovascular end points or atherosclerotic plaque
burden. The immune system is composed of a hierarchically organized set of molecular and
cellular networks that act in concert in tissues and systemically. Yet, most studies of the role of
immune system in atherosclerosis in humans have focused on circulating cells—with little or no
focus on cellular immune infiltrates at the tissue site or the relationship between them. To gain a
better understanding of systemic and local immune networks that contribute to CVD, we will
take advantage of technological advances in molecular systems biology. Using CyTOF mass
cytometry—a cutting-edge technique for high-dimensional analysis of immune cells—we
identified single-cell variation and molecular activation of circulating peripheral blood
mononuclear cells (PBMCs) and atherosclerotic tissue-associated immune cells in patients with
carotid artery disease undergoing surgical revascularization. We will use a multi-tissue, systems
biology approach to infer arterial wall- and blood-specific immune networks that govern the
immune response at different stages of atherosclerosis. We will combine the use of innovative
technologies such as CyTOF and RNA next-generation (NGS) to identify immune regulatory
network relevant to human CVD disease. In specific Aim 1, we will identify the single-cell
composition and molecular state of circulating and tissue-associated human immune cells. We
will also determine the molecular and cellular correlates between systemic and tissue immune
cell diversity and atherosclerotic and clinical phenotypes. In Specific Aim 2, we will identify
immune networks in atherosclerosis and the clinical correlates of identified immune networks
activated in atherosclerosis. The use of systems biology studies that integrate cutting-edge
technologies to measure immune cell variation in patient samples to infer immune regulatory
networks will deepen our knowledge of the contribution of the immune system to CVD and will
set the stage to the selection of molecular targets for novel anti-inflammatory therapies.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chiara Giannarelli其他文献
Chiara Giannarelli的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chiara Giannarelli', 18)}}的其他基金
Mechanisms of atherosclerotic cardiovascular complications in COVID19
新冠肺炎动脉粥样硬化性心血管并发症的机制
- 批准号:
10512449 - 财政年份:2022
- 资助金额:
$ 8.48万 - 项目类别:
Network-driven drug repurposing in cardiovascular disease: NDRA clinical trial planning
网络驱动的心血管疾病药物再利用:NDRA 临床试验规划
- 批准号:
10195846 - 财政年份:2021
- 资助金额:
$ 8.48万 - 项目类别:
Dissecting the role of CD8+ T cells in atherosclerosis
剖析 CD8 T 细胞在动脉粥样硬化中的作用
- 批准号:
10034860 - 财政年份:2020
- 资助金额:
$ 8.48万 - 项目类别:
Dissecting the role of CD8+ T cells in atherosclerosis
剖析 CD8 T 细胞在动脉粥样硬化中的作用
- 批准号:
10630050 - 财政年份:2020
- 资助金额:
$ 8.48万 - 项目类别:
Dissecting the role of CD8+ T cells in atherosclerosis
剖析 CD8 T 细胞在动脉粥样硬化中的作用
- 批准号:
10242145 - 财政年份:2020
- 资助金额:
$ 8.48万 - 项目类别:
Dissecting the role of CD8+ T cells in atherosclerosis
剖析 CD8 T 细胞在动脉粥样硬化中的作用
- 批准号:
10399349 - 财政年份:2020
- 资助金额:
$ 8.48万 - 项目类别:
Dissecting the cellular and molecular immune interactions in human atherosclerosis
剖析人类动脉粥样硬化中的细胞和分子免疫相互作用
- 批准号:
9350388 - 财政年份:2016
- 资助金额:
$ 8.48万 - 项目类别:
Role of alternatively spliced Tissue Factor in atherosclerosis
选择性剪接组织因子在动脉粥样硬化中的作用
- 批准号:
8443278 - 财政年份:2013
- 资助金额:
$ 8.48万 - 项目类别:
Role of alternatively spliced Tissue Factor in atherosclerosis
选择性剪接组织因子在动脉粥样硬化中的作用
- 批准号:
8723269 - 财政年份:2013
- 资助金额:
$ 8.48万 - 项目类别:
Role of alternatively spliced Tissue Factor in atherosclerosis
选择性剪接组织因子在动脉粥样硬化中的作用
- 批准号:
9285823 - 财政年份:2013
- 资助金额:
$ 8.48万 - 项目类别:
相似海外基金
Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
- 批准号:
23K07659 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
- 批准号:
23K15705 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
- 批准号:
23K19490 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
- 批准号:
10697567 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
- 批准号:
10727765 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
- 批准号:
23K13905 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
- 批准号:
23K08467 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
- 批准号:
493138 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
- 批准号:
2223225 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别:
Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
- 批准号:
10651054 - 财政年份:2023
- 资助金额:
$ 8.48万 - 项目类别: